When John identifies a strategic exit point, he will send you an alert with specific trade information as to what security to sell, when to sell it, and at what price. Most often, it will be to TAKE PROFITS, but on rare occasions, it will be to exercise a STOP LOSS at a predetermined price to adhere to strict risk management discipline. Read more
(POWER PRODUCERS WILL BE ONE OF THE BIG INVESTMENTS OF THE FUTURE)
October 18, 2024
Hello everyone.
The bullish argument for nuclear power generation.
Vistra (VST) $127.27, Constellation Energy (CEG) $271.20, Talen Energy (TLN)$171.68, Cameco Corp. (CCJ)$56.67
There are strong trends in both energy supply and demand that support the fundamentals of existing nuclear power producers.
Beginning with the supply argument, nuclear power plants are a highly valuable and scarce asset.
Nuclear power plants are valuable because nuclear is the only source of carbon-free energy that is reliable enough to be considered "base load energy." Other sources of reliable energy are either dirty (fossil fuels), are not yet reliable (solar, wind), or are not abundant (hydro, geothermal).
The US has agreed to phase out coal and other dirty power sources over time. Coal used to account for one-third of power generation but now accounts for roughly 10%. This supply gap has largely been filled by natural gas and crude oil (see below chart). Nuclear was previously vilified as a dangerous source of electricity; however, politicians on both sides have become much more pro-nuclear in recent years as an increasingly attractive alternative. This has led to several nuclear plant extensions, talks of restarts, and new tax incentives.
Nuclear power is scarce because it is extremely costly and timely to build. Almost all US nuclear reactors were built between 1967 and 1990. Regulatory costs skyrocketed after the Three Mile Island accident in 1979. The Vogtle electric plant in Georgia was the only new nuclear plant added in the last 30 years. Vogtle took 15 years and $30 billion to build. Nuclear power plants just aren't economically viable relative to the cost of building new natural gas plants. However, this makes existing plants, like the one Talen owns, more valuable.
Moving on to the demand argument, electricity demand growth is accelerating as the US adopts electric cars and builds more data centers.
Electricity demand has historically grown in line with population growth; however, recent technology shifts have accelerated the demand on the grid. Artificial intelligence applications are more compute-intensive and, therefore, require more electricity. For example, ChatGPT uses as much as 30x more electricity per query than Google search. Research from the Boston Consulting Group projects data center energy use in the US will 3x from 130 terawatt hours in 2022 to 390 terawatt hours by 2030.
JPMorgan analysts are seeing “structural tailwinds, including manufacturing onshoring, broader electrification trends (transportation, heating, and more), as well as data center development underpinning a paradigm shift in power demand.”
Additionally, analysts see that with half of its gas generation in the Texas ERCOT grid, Vistra can also help fill a potential 40-gigawatt supply gap in the Lone Star State by 20230.
Vistra (VST) is JPMorgan’s top pick, with a price target of $178.
Vistra Energy (VST) Daily Chart
Constellation Energy (CEG) is another favourite of JPMorgan in this sector, and the investment bank believes Constellation’s industry-leading nuclear fleet is well-positioned to continue capturing long-term power contracts with data centre developers at premium prices. Its decision to restart Three Mile Island after signing a power purchase agreement with Microsoft was an industry milestone.
JPMorgan’s price target for Constellation is $342.
Constellation Energy (CEG) Daily chart
Finally, JPMorgan analysts see Talen’s multidecade agreement with Amazon Web Services to power a data centre campus with electricity generated at the Susquehanna nuclear plant in Pennsylvania could help send the stock higher if it delivers the full 960 megawatts of power to AWS.
Over the next 10 years, AWS has contracted to purchase as much as 1 gigawatt of power per year for a price nearly double the rate of the wholesale power price. Amazon is willing to pay a premium to source reliable carbon-free energy for a large data center, and it will also benefit from certain tax credits associated with the project.
Finally, there may be additional opportunities for per-share value growth above and beyond the AWS deal. Talen believes there are additional opportunities to co-locate data centers next to its other power plants. Talen's capital allocation strategy of creatively monetizing existing assets while returning capital to shareholders should continue to work.
It is important to remember that there is a wide moat around the business simply because a new nuclear power plant of Susquehanna's scale cannot be replicated at a cost anywhere near the current enterprise value of Talen.
JPMorgan’s price target for Talen is $268.
Talen Energy (TLN)
Cameco Corp. (CCJ) is a great nuclear power play stock to own for the long term, too. I have been recommending this stock since early 2024.
Cameco Corp. (CCJ) Daily Chart
I would recommend owning at least two of the power produces illustrated here. Scaling in is the strategy you should use.
Earnings Results
Netflix: Earnings yesterday beat on the top and bottom lines. Ad-tier memberships jumped 35% quarter over quarter. Revenue for the full year of 2025 is expected to be between $43 billion and $44 billion. Advertising is expected to become a primary growth driver from 2026 onwards.
I recommended Netflix on January 17, 2024, when it was $480.00. I also recommended you either start scaling into the stock or add weight in Jacquie’s Post on October 10.
Goldman Sachs (GS) and JPMorgan (JPM) also reported great earnings. I also recommended these stocks, or to add weight if you held them, in Jacquie’s Post on October 10.
QI CORNER
SOMETHING TO THINK ABOUT
TRIVIA CORNER
- Which country has the longest coastline?
- Who was the first U.S. billionaire?
- Which first lady was the first to appear on U.S. currency?
Answers in Monday’s Post.
Cheers
Jacquie
When John identifies a strategic exit point, he will send you an alert with specific trade information as to what security to sell, when to sell it, and at what price. Most often, it will be to TAKE PROFITS, but, on rare occasions, it will be to exercise a STOP LOSS at a predetermined price to adhere to strict risk management discipline. Read more
Global Market Comments
October 18, 2024
Fiat Lux
Featured Trade:
(HOW TO FIND A GREAT OPTIONS TRADE)
You’ve spent vast amounts of time, money, and effort to become an options trading expert.
You know the difference between bids and offers, puts and calls, exercise prices, and expiration days.
And you still can’t make any money.
Now What?
Where do you apply your newfound expertise? How do you maximize your reward while minimizing your risk?
It is all very simple.
Stick to five basic disciplines, and you will suddenly find that the number of your new trades that are winners takes a quantum leap, and money will start pouring into your trading account.
It’s really not all that hard to do. So here we go!
1) Know the Macro Picture
If you have a handle on whether the economy is growing or shrinking, you have a major advantage in the options market.
In a growing economy, you only want to employ bullish strategies, like calls, call spreads, and short volatility plays.
In a shrinking economy, you want to execute bearish plays, like puts, put spreads, and long volatility plays.
Remember, the only thing that is useful for your options trading is a view of what the economy is going to do NEXT.
The government only publishes historical economic data, which is, for the most part, useless in predicting what is going to happen in the future.
The options market is all about discounting what is going to happen next.
And how do you find that out?
Well, you could hire your own in-house staff economist. Or you could rely on economic research from the largest brokerage houses.
Even the Federal Reserve puts out its own forecasts for economic growth prospects.
However, all of these sources have notoriously poor track records. Listening to them and placing bets on their advice CAN get you into a world of trouble.
For the best possible read on the future of the US and the global economy, there is no better place to go than Global Trading Dispatch, published by me, John Thomas, the Mad Hedge Fund Trader.
This is where the largest hedge funds and brokers go to find out what really is going to happen to the economy.
Do you want to give yourself another valuable edge?
There are over 100 different industries listed on the US stock markets. However, only about 5 or 10 are really growing decisively at any particular time. The rest are either going nowhere or are shrinking.
In fact, you can find a handful of sectors that are booming while others are in outright recession.
If you are a major hedge fund, institution, or government, you may want to cover all 100 of those industries. Good luck with that.
If you are a small hedge fund or an individual working from home, you will want to conserve your time and resources, skip most of the US industry, and only focus on a handful.
Some traders take this a step further and only concentrate on a single high-growing, volatile industry, like technology or biotech, or even a single name, like Netflix (NFLX), Tesla (TSLA), or Amazon (AMZN).
How do you decide which industry to trade?
Brokerage houses pump out more free research than you could ever read in a lifetime. Government reports tend to be stodgy, boring, and out of date. Big hedge funds keep their in-house research confidential (although some of it leaks out to me).
The Mad Hedge Fund Trader solves this problem for you by limiting its scope to a small number of benchmark pathfinder industries, like technology, banks, energy, consumer cyclicals, biotech, and cyber security.
In this way, we gain a handle on what is happening in the economy as a whole while lining up rifle shots on the best options trades out there.
We want to direct you to where the action is and where we have a good handle on future earnings prospects.
It doesn’t hurt that we live on the edge of Silicon Valley and get invited to test out many new technologies before they are made public. My Tesla Model S1 is a perfect example.
That encouraged me to recommend Tesla stock at $16 before it began its historic run to $295. It was the best short squeeze ever.
2) The Micro Picture is Ideal
Once you have a handle on the economy and the best industries, it’s time to zero in on the best company to trade in or the “MICRO” selection.
It’s always great to find a good target to trade in because positions in single companies can deliver double or even triple the returns compared to stock indexes.
That is because the market will pay a far higher implied volatility for a single company than for a large basket of companies.
Remember also that you are taking greater risks in trading with individual companies. The options market will pay you for that extra risk.
If the earnings come through as expected, everything is hunky dory. If they don’t, the shares can drop by half in a heartbeat. Large indexes buffer this effect, which is why they have far lower volatility.
Of course, there are gobs of market research about individual companies out there from brokers. Some of it is right, some of it is wrong, but all of it is conflicted. Recommendations are either “BUY” or “HOLD”.
Brokers are loath to issue a “SELL” recommendation for a stock because it will eliminate any chance of that firm obtaining new issue business. Who wants to hire a broker to sell new stock when their analyst has already dissed the company?
And brokerage firms don’t make their bread and butter on those piddling little discount commissions you have been paying them. They make it on new highly lucrative new issues business. In fact, a new issue can earn as much as $100 million from one firm. I know because I’ve done it.
I have been following about 100 companies in the leading market sectors for nearly half a century. Some of the managers of these firms have become close friends over the decades. So, I get some really first-class information.
When markets rotate to sectors and companies that I already know, I have a huge advantage. Needless to say, this gives me a massive head start when selecting individual names for options Trade Alerts.
3) The Technicals Line Up
I have never been a huge fan of technical analysis.
Most technical advice boils down to “If it’s gone up, it will go up more” or “If it’s gone down, it will go down more.”
Over time, the recommendations are accurate 50% of the time or are about equal to a coin toss.
However, the shorter the time frame, the more useful technical analysis becomes.
If you analyze intraday trading, almost all very short-term movements can be explained in technical terms. This is entirely how day traders make their living.
It’s a classic case of if enough people believe something, it becomes true, no matter how dubious the underlying facts may be.
So, it does behoove us to pay some attention to the charts when executing our trades.
Talk to old-time investors, and you will find that they use fundamentals for long-term stock selection and technicals for short-term order execution.
Talk to them some more, and you find the best fundamentalists sound like technicians, while savvy technicians refer to underlying fundamentals.
Get the technicals right, and you can provide one additional reason for your trade to work.
4) The Calendar is Favorable
There is one more means of assuring your trades turn into winners.
I am a big fan of buying straw hats in the dead of winter and umbrellas in the sizzling heat of the summer.
There IS a method to my madness.
Have you heard of “Sell in May and go away?”
According to the Stock Trader’s Almanac, $10,000 invested at the beginning of May and sold at the end of October every year since 1950 would be showing a loss today.
This is despite the fact that the Dow Average rocketed from $409 to $18,300 during the same time period, a gain of 44.74 times!
Amazingly, $10,000 invested every November and sold at the end of April would today be worth $702,000, giving you a compound annual return of 7.10%.
It gets better.
Of the 62 years under study, the market was down in 25 of the May to October periods but negative in only 13 of the November to April periods.
What’s more, the market has been down only three times from November to April in the last 20 years!
There have been just three times when the "good 6 months" have lost more than 10% (1969, 1973, and 2008), but with the "bad six months" time period, there have been 11 losing losses of 10% or more.
So, it’s clear that trading according to the calendar can have a significant impact on your profitability.
Being a long-time student of the American, and indeed, the global economy, I have long had a theory behind the regularity of this cycle. It’s enough to base a pagan religion around, like the once-practicing Druids at Stonehenge.
Up until the 1920’s, we had an overwhelmingly agricultural economy. Farmers were always in maximum financial distress in the fall, when their outlays for seed, fertilizer, and labor were the greatest, but they had yet to earn any income from the sale of their crops.
So they had to borrow all at once, placing a large cash call on the financial system as a whole. This is why we have seen so many stock market crashes in October.
Once the system swallows this lump, it’s nothing but green lights for six months.
After the cycle was set and was easily identifiable by computer algorithms, the trend became a self-fulfilling prophecy.
Yes, it may be disturbing to learn that we ardent stock market practitioners might, in fact, be the high priests of a strange set of beliefs. But hey, some people will do anything to outperform the market.
It is important to remember that this cyclicality is not 100% accurate, and you know the one time you bet the ranch, it won’t work.
Benefits of the Tailwinds
So there we have it.
Adopt these five simple disciplines, and you will find your success rate on trades jumps from a mere coin toss to 70%, 80%, or even 90%.
In other words, you convert your trading from an endless series of frustrations to a reliable source of income.
If a potential trade meets only four of these five criteria, please do it with your money and not mine. Your chances of making money have just declined.
And I bet a lot of you poor souls execute trades all the time that meet NONE of these criteria. No wonder you’re losing money hand over fist!
Get the tailwinds of the economy, your industrial call, your company picks, the market technicals, and the calendar working for you, and all of a sudden, you’re a trading genius.
It only took me half a century to pull all this together. Hopefully, you can learn a little bit faster than me.
I hope it all works for you.
Your Guide to Winning Trades
“In a social democracy with a fiat currency, all roads lead to inflation,” said legendary hedge fund manager Bill Fleckenstein.
When John identifies a strategic exit point, he will send you an alert with specific trade information as to what security to sell, when to sell it, and at what price. Most often, it will be to TAKE PROFITS, but, on rare occasions, it will be to exercise a STOP LOSS at a predetermined price to adhere to strict risk management discipline. Read more
Mad Hedge Biotech and Healthcare Letter
October 17, 2024
Fiat Lux
Featured Trade:
(NO TEARS HERE)
(JNJ)
If you've been following my adventures in the market jungle for any length of time, you know I've got a nose for opportunity that'd make a bloodhound jealous. Well, folks, that nose is twitching something fierce, and it's pointed straight at Johnson & Johnson (JNJ).
Now, I know what you're thinking: "John, J&J? Aren't they as exciting as watching paint dry?" Before you dismiss this company, let me tell you—this isn't your grandma's Band-Aid shop anymore.
First off, let's talk about their pharmaceutical arm. It's not just flexing; it's practically bench-pressing the competition with one hand tied behind its back. I'm talking about a lineup that includes immunology juggernauts like Stelara and Tremfya, and cancer-fighting dynamos such as Darzalex and Erleada.
But here's the kicker—they've got over 40 late-stage clinical trials cooking. That's no mere pipeline; it's a veritable gusher of potential blockbusters.
The surprises from J&J don't end there. They recently spun off their consumer health unit faster than you can say "No more tears." Why? To zero in on their real money-makers: pharmaceuticals and medical devices. It's like watching a prizefighter shed weight before a title bout—leaner, meaner, and ready to deliver a knockout punch to the market.
Speaking of punches, J&J has been on an acquisition spree that'd make a Silicon Valley startup blush. On October 9th, they snatched up V-Wave for a cool $1.7 billion, adding to their previous grabs of Abiomed ($16.6 billion in 2022) and Shockwave Medical ($13.1 billion in 2024). And if you think they're splurging just for the heck of it, think again. This triple play gives J&J a solid foothold in the $60 billion cardiovascular device market, which is growing at a heart-racing 8% annually.
So, what does V-Wave bring to a giant like J&J? It's not just another cog in the medical machine. V-Wave is developing innovative treatment options for heart failure patients. Their device has already snagged the FDA's breakthrough device designation in 2019 and Europe's CE mark in 2020. For J&J, this means they can hit the ground running, spreading V-Wave's Ventura Interatrial Shunt across the globe faster than you can say "cardiovascular revolution."
As for their Q3 results? Let's just say J&J didn't settle for merely meeting expectations—they exceeded them. We're looking at a 5.4% adjusted operational revenue growth, with their cardiovascular business shooting up 26.5% year-over-year.
Now, I'm no fortune teller—if I were, I'd be writing this from my private island—but I'd bet my favorite Bloomberg terminal that their cardiovascular business is going to keep pumping life into J&J's MedTech segment. With more folks lining up for cardiovascular procedures than a Black Friday sale, J&J is poised to ride this wave like a pro surfer at Pipeline.
Of course, it's not all sunshine and rainbows. Their China business is facing more headwinds than a kite in a hurricane, thanks to an anti-corruption campaign that's thrown a monkey wrench into their marketing machine.
But hey, this is J&J we're talking about—a company that's been around since Grover Cleveland was in the White House. They've seen tougher times than this and come out swinging.
So, what's the bottom line? I'm slapping a "Buy" rating on this stock, with a fair value of $195 per share. For those of you looking for a stock that combines the stability of a mountain with the growth potential of a tech startup, J&J might just be your golden ticket.
Now, if you'll excuse me, I've got a sudden urge to go check my own blood pressure after all this excitement.
P.S. If J&J ever decides to venture into stem cell therapy for aging knees, you can bet I'll be first in line. These well-worn joints have a few more mountains to climb!
Global Market Comments
October 17, 2024
Fiat Lux
Featured Trade:
(FRIDAY OCTOBER 25 SALT LAKE CITY UTAH STRATEGY LUNCHEON)
(THIS IS NOT YOUR FATHER’S NUCLEAR POWER PLANT)
(SMR), (MSFT), (GOOGL), (AMZN)
Legal Disclaimer
There is a very high degree of risk involved in trading. Past results are not indicative of future returns. MadHedgeFundTrader.com and all individuals affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as investment advice. Information for futures trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of MadHedgeFundTrader.com may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.